Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | September 15, 2026 | September 15, 2026 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Finance CFO | February 02, 2024 | February 06, 2024 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | January 12, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,184 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 1,000 · Balance 8,184 |
REGENERON PHARMACEUTICALS, INC.
Report date February 02, 2024 · Filed February 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,693 |
Ending reported balance
After 2024-02-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-02-02 · Exercise / conversion · Acquired 400 · Balance 23,974 Row 2 · 2024-02-02 · Tax withholding · Disposed 281 · Balance 23,693 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $378.98 · Expires 2027-12-12 | Direct | 11,787 |
Reported balance
After 2024-02-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-02 · Exercise / conversion · Disposed 400 · Balance 11,787 F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 270 |
Reported balance
Holding disclosure · report date 2024-02-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 270 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 11,500 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 11,500 · Balance 11,500 F1: Stock options vest on January 12, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2027-01-12 | Direct | 7,700 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Grant · Acquired 7,700 · Balance 7,700 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3: RSUs vest on January 12, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on January 12, 2027.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F3: RSUs vest on January 12, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2020 Filed Apr 3, 2020 20:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 99 | $493.51 | $48,857.49 |
DisclosureSEC source: 0001708138-20-000030 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,761 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 99 shares of Company stock on April 3, 2020 at prices ranging from $493.02 to $493.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 3, 2020 at each separate price. Read SEC document |
| April 03, 2020 Filed Apr 3, 2020 20:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 25 | $492.76 | $12,319.00 |
DisclosureSEC source: 0001708138-20-000030 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,860 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 03, 2020 Filed Apr 3, 2020 20:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 50 | $490.66 | $24,533.00 |
DisclosureSEC source: 0001708138-20-000030 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,885 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 50 shares of Company stock on April 3, 2020 at prices ranging from $490.45 to $490.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 3, 2020 at each separate price. Read SEC document |
| April 03, 2020 Filed Apr 3, 2020 20:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 121 | $489.50 | $59,229.50 |
DisclosureSEC source: 0001708138-20-000030 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,935 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000030 · edgardoc.xml · derivative · entry 18 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 3,000 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. F10 · balance_after: Form two of two Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 25 | $497.48 | $12,437.00 |
DisclosureSEC source: 0001708138-20-000030 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,056 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11 | $496.28 | $5,459.08 |
DisclosureSEC source: 0001708138-20-000030 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,081 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 69 | $495.24 | $34,171.56 |
DisclosureSEC source: 0001708138-20-000030 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,092 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 69 shares of Company stock on April 2, 2020 at prices ranging from $495.15 to $495.31. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 91 | $494.68 | $45,015.88 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 30 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,161 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · price: Represents volume-weighted average price of sales of 91 shares of Company stock on April 2, 2020 at prices ranging from $494.00 to $494.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. F18 · balance_after: Form one of two Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 146 | $493.54 | $72,056.84 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 29 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,252 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · price: Represents volume-weighted average price of sales of 146 shares of Company stock on April 2, 2020 at prices ranging from $493.01 to $493.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 109 | $492.60 | $53,693.40 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 28 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,398 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 109 shares of Company stock on April 2, 2020 at prices ranging from $492.37 to $492.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 85 | $491.72 | $41,796.20 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 27 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,507 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 85 shares of Company stock on April 2, 2020 at prices ranging from $491.64 to $491.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 51 | $490.11 | $24,995.61 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 26 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,592 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 128 | $489.39 | $62,641.92 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 25 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,643 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 128 shares of Company stock on April 2, 2020 at prices ranging from $489.07 to $489.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 246 | $488.55 | $120,183.30 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 24 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,771 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 246 shares of Company stock on April 2, 2020 at prices ranging from $488.02 to $488.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 91 | $487.29 | $44,343.39 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 23 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,017 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 91 shares of Company stock on April 2, 2020 at prices ranging from $487.04 to $487.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 78 | $486.66 | $37,959.48 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 22 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,108 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 78 shares of Company stock on April 2, 2020 at prices ranging from $486.62 to $486.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 62 | $485.63 | $30,109.06 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 21 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,186 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 62 shares of Company stock on April 2, 2020 at prices ranging from $485.01 to $485.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 22 | $484.96 | $10,669.12 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 20 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,248 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 139 | $483.51 | $67,207.89 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 19 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,270 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 139 shares of Company stock on April 2, 2020 at prices ranging from $483.28 to $483.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,317 | $492.05 | $1,140,079.85 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 18 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,409 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,000 | $272.70 | $818,100.00 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 17 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000030 · edgardoc.xml · derivative · entry 17 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,500 Underlying: Common Stock · 1,500 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000030 · edgardoc.xml · derivative · entry 16 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 2,000 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000030 · edgardoc.xml · derivative · entry 15 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 2,500 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,162 | $488.20 | $567,288.40 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 16 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,726 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,500 | $272.70 | $409,050.00 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 15 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,549 | $488.22 | $756,252.78 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 14 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,388 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $272.70 | $545,400.00 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 13 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,936 | $488.22 | $945,193.92 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 12 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,937 Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,500 | $272.70 | $681,750.00 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 11 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 156 | $493.08 | $76,920.48 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 10 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,373 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 156 shares of Company stock on April 1, 2020 at prices ranging from $493.00 to $493.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 64 | $492.61 | $31,527.04 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 9 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,529 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 64 shares of Company stock on April 1, 2020 at prices ranging from $492.07 to $492.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 87 | $490.70 | $42,690.90 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 8 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,593 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 87 shares of Company stock on April 1, 2020 at prices ranging from $490.41 to $490.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 61 | $489.46 | $29,857.06 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,680 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 61 shares of Company stock on April 1, 2020 at prices ranging from $489.44 to $489.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 23 | $488.77 | $11,241.71 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,741 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 23 | $486.27 | $11,184.21 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,764 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $484.14 | $484.14 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,787 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 87 | $481.91 | $41,926.17 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,788 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 87 shares of Company stock on April 1, 2020 at prices ranging from $481.85 to $481.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 75 | $479.50 | $35,962.50 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,875 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 75 shares of Company stock on April 1, 2020 at prices ranging from $479.06 to $479.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 23 | $478.97 | $11,016.31 |
DisclosureSEC source: 0001708138-20-000029 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,950 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 26, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 34 | $460.05 | $15,641.70 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 22 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,973 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 34 shares of Company stock on February 26, 2020 at prices ranging from $460.03 to $460.07. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 27 | $458.35 | $12,375.45 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 21 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,007 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 27 shares of Company stock on February 26, 2020 at prices ranging from $458.11 to $458.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 25 | $457.23 | $11,430.75 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 20 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,034 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 25 shares of Company stock on February 26, 2020 at prices ranging from $457.10 to $457.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $456.67 | $4,566.70 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 19 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,059 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 26, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 32 | $455.37 | $14,571.84 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 18 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,069 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 32 shares of Company stock on February 26, 2020 at prices ranging from $455.24 to $455.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18 | $454.85 | $8,187.30 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 17 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,101 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 26, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 44 | $453.36 | $19,947.84 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 16 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,119 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 44 shares of Company stock on February 26, 2020 at prices ranging from $453.04 to $453.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $452.04 | $4,520.40 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 15 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,163 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · derivative · entry 25 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,500 Underlying: Common Stock · 1,000 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.